Q1 Earnings Forecast for Immunocore Issued By HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Free Report) – Equities research analysts at HC Wainwright reduced their Q1 2027 earnings per share estimates for Immunocore in a report issued on Tuesday, November 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.17 per share for the quarter, down from their prior estimate of $0.18. HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Immunocore’s Q2 2027 earnings at $0.26 EPS, Q4 2027 earnings at $0.52 EPS and FY2027 earnings at $1.34 EPS.

Other research analysts also recently issued reports about the stock. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. Mizuho upped their target price on shares of Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, October 15th. Morgan Stanley set a $43.00 target price on shares of Immunocore in a research note on Friday, August 7th. Finally, Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Get Our Latest Stock Report on IMCR

Immunocore Stock Down 3.7%

IMCR stock opened at $30.48 on Wednesday. The company has a fifty day moving average price of $31.22 and a 200 day moving average price of $31.66. Immunocore has a 12 month low of $27.50 and a 12 month high of $40.71. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -46.89 and a beta of 0.82. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.62 and a quick ratio of 4.44.

Immunocore (NASDAQ:IMCR – Get Free Report) last announced its earnings results on Friday, November 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The business had revenue of $102.22 million for the quarter, compared to analysts’ expectations of $152.09 million. Immunocore had a negative return on equity of 7.96% and a negative net margin of 7.48%.

Institutional Investors Weigh In On Immunocore

Several hedge funds have recently modified their holdings of IMCR. GAMMA Investing LLC grew its position in Immunocore by 202.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $61,000 after buying an additional 1,286 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Immunocore during the 3rd quarter worth $72,000. Juncture Wealth Strategies LLC purchased a new position in Immunocore during the 3rd quarter worth $207,000. denkapparat Operations GmbH acquired a new stake in shares of Immunocore in the 2nd quarter worth $209,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Immunocore by 27.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,252 shares of the company’s stock worth $285,000 after acquiring an additional 1,975 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.

More Immunocore News

Investors following IMCR have been watching these news items:

Immunocore Company Profile

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

Featured Stories

Earnings History and Estimates for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.